title: Phase III trial of Rapamune versus placebo in primary renal allograft recipients.
authors.affiliation: IRCCS Ospedale Maggiore di Milano, Halifax, Nova Scotia, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Ponticelli
authors.forename: A S
authors.initials: AS
authors.lastname: MacDonald
authors.forename: P
authors.initials: P
authors.lastname: Rajagopalan
authors.forename: R
authors.initials: R
authors.lastname: Sindhi
authors.forename: T
authors.initials: T
authors.lastname: Mathew
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology; D010919:Placebos; D011183:Postoperative Complications / Q000453:epidemiology; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D014280:Triglycerides / Q000097:blood
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D010919:Placebos; D014280:Triglycerides; D016572:Cyclosporine; D020123:Sirolimus